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ARTICLE
A multiethnic genome-wide association study of
primary open-angle glaucoma identifies novel risk
loci
Hélène Choquet 1, Seyyedhassan Paylakhi2, Stephen C. Kneeland3, Khanh K. Thai1, Thomas J. Hoffmann4,5,
Jie Yin1, Mark N. Kvale4, Yambazi Banda4, Nicholas G. Tolman3, Pete A. Williams 3, Catherine Schaefer1,
Ronald B. Melles6, Neil Risch1,4,5, Simon W.M. John3, K. Saidas Nair2,7 & Eric Jorgenson 1
Primary open-angle glaucoma (POAG) is a leading cause of irreversible vision loss, yet much
of the genetic risk remains unaccounted for, especially in African-Americans who have a
higher risk for developing POAG. We conduct a multiethnic genome-wide association study
(GWAS) of POAG in the GERA cohort, with replication in the UK Biobank (UKB), and vice
versa, GWAS in UKB with replication in GERA. We identify 24 loci (P < 5.0 × 10−8), including
14 novel, of which 9 replicate (near FMNL2, PDE7B, TMTC2, IKZF2, CADM2, DGKG, ANKH,
EXOC2, and LMX1B). Functional studies support intraocular pressure-related influences of
FMNL2 and LMX1B, with certain Lmx1b mutations causing high IOP and glaucoma resembling
POAG in mice. The newly identified loci increase the proportion of variance explained in each
GERA race/ethnicity group, with the largest gain in African-Americans (0.5–3.1%). A meta-
analysis combining GERA and UKB identifies 24 additional loci. Our study provides important
insights into glaucoma pathogenesis.
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G laucoma is a progressive optic neuropathy caused by acombination of genetic and environmental factors and isthe leading cause of irreversible blindness worldwide1. It
is a heterogenous group of diseases, unified by a loss of retinal
ganglion cells (RGCs) and the degeneration of their axons in the
optic nerve, leading to associated visual field defects. Primary
open-angle glaucoma (POAG) is the most common form of
glaucoma2 and is often associated with elevated intraocular
pressure (IOP), although up to one-third of POAG patients have
IOP levels in the normal range3. In addition to high IOP, major
risk factors for POAG include advancing age, myopia, race/eth-
nicity, and positive family history2,4.
Characterizing the genetic factors influencing an individual’s
susceptibility to POAG is an important step toward under-
standing its etiology. A twin study, published in 1987, estimated
the heritability of POAG at 0.135. More recently, two studies
based on genome-wide array data of unrelated individuals esti-
mated the additive heritability of POAG to range from 24 to 42%,
but with inconsistent results between the two studies6,7. Genome-
wide association studies (GWASs) have reported 17 loci asso-
ciated with POAG at genome-wide significance, and an additional
2 loci at a suggestive level of significance (P < 10−6)8–18. Together
these loci explain only a small proportion of the genetic con-
tribution to POAG risk, and although most of the reported
associations have been validated in an independent study,
only a few have been investigated in functional studies (e.g.,
CDKN2B-AS, SIX6, and CAV1/2)19–22. There is also a lack of
studies investigating genetic risk factors influencing POAG sus-
ceptibility in African ancestry populations and Hispanic/Latino
individuals, with only one GWAS published to date14. This is a
particularly important gap in our understanding of glaucoma
etiology, because of the higher prevalence of POAG in these
populations (https://nei.nih.gov/health/glaucoma/glaucoma_
facts).
To address these gaps, we undertake a GWAS of POAG and an
analysis of genetic ancestry in the large and ethnically diverse
Genetic Epidemiology Research in Adult Health and Aging
(GERA) cohort, consisting of 4 986 POAG cases and 58 426
controls from four race/ethnicity groups (non-Hispanic whites,
Hispanic/Latinos, East Asians, and African-Americans). We test
novel loci discovered in the current study in an independent
external replication cohort: the multiethnic UK Biobank (UKB)23,
which includes 7 329 glaucoma cases (subtype unspecified) and
169 561 controls. Conversely, we then investigate novel
glaucoma-associated loci from the UKB in GERA, and conduct a
multiethnic meta-analysis combining GERA and UKB. We also
examine the effect of newly and previously identified POAG loci
on the ancestry effects observed in GERA. In addition to
undertaking in silico analyses of associated loci, we examine
changes in the expression of candidate genes in RGCs and
optic nerve head tissue isolated from a mouse model of glaucoma
as a mean of identifying genes that potentially contribute to
glaucomatous neurodegeneration. Next, we perform functional
characterization of FMNL2 and LMX1B, two of our novel asso-
ciated loci. First, employing an small interfering RNA (siRNA)-
mediated gene silencing of FMNL2, we determine a role for
FMNL2 in supporting the function of human trabecular mesh-
work (HTM) cells, a critical cell type involved in the regulation of
IOP. Second, utilizing mutant mouse strains, we demonstrate
support for a role of LMX1B in the pathogenesis of ocular
hypertension (OHTN) and glaucoma in the general population.
The current study identifies a total of nine novel loci associated
with the risk of POAG or glaucoma at genome-wide significance
that replicated in an independent sample, and demonstrates
relevant function of FMNL2 and LMX1B using cell line and
mouse experiments.
Results
GERA cohort. We conducted the primary discovery analysis in
4 986 POAG cases and 58 426 controls from 4 race/ethnicity
groups (non-Hispanic whites, Hispanic/Latinos, East Asians, and
African-Americans) in GERA (Table 1). Among GERA subjects,
cases were more likely to be older and male. We also observed a
much higher prevalence of POAG among African-Americans
compared to non-Hispanic whites (16.1% vs. 7.4%), along with a
less-pronounced higher prevalence in East Asians (9.9%) and
Hispanic/Latinos (7.9%)
Because of the observed variation in POAG prevalence, we
examined POAG prevalence in the context of genetic ancestry
within each of the four race/ethnicity groups (Fig. 1, Supple-
mentary Table 1). In the African-American group, we observed a
significant association (P= 0.01) between increasing POAG risk
and greater African (compared to European) ancestry (PC1). In
the East Asian group, we observed a greater risk of POAG with
northern (vs. southern) East Asian ancestry (P= 7.3 × 10−8)
(PC2). In the Hispanic/Latino group, we observed higher risk of
POAG with greater Native American (vs. European) ancestry
(P= 6.3 × 10−8) (PC1).
Glaucoma loci in GERA. In our discovery GWAS analysis, we
identified 12 independent genome-wide significant (P < 5 × 10−8)
loci associated with POAG in the multiethnic meta-analysis
(λ= 1.056 and λ1000= 1.006, which is reasonable for a sample of
this size under the assumption of polygenic inheritance24)
(Table 2, and Supplementary Figure 1, Supplementary Figure 2).
Of the 12 loci, 5 were novel (41.7%), including rs56117902 in
FMNL2 (odds ratio (OR)= 0.88, P= 1.0 × 10−8), rs9494457 in
PDE7B (OR= 1.16, P= 3.0 × 10−11), rs149154973 near ELN
(OR= 0.70, P= 3.9 × 10−9), rs324794 near TMTC2 (OR= 0.87,
P= 6.1 × 10−10), and rs2593221 in TCF12 (OR= 0.86, P= 8.5 ×
10−10) (Supplementary Figure 3). We also examined the asso-
ciation of the lead single-nucleotide polymorphisms (SNPs) at the
12 genome-wide significant loci with POAG in each individual
race/ethnicity group (Supplementary Table 2 and Supplementary
Figure 1). In African-Americans, SNPs rs56117902 at FMNL2
and rs149154973 near ELN were both nominally associated with
POAG (P= 0.017 and 0.047 for rs56117902 and rs149154973,
respectively). In Hispanic/Latinos, we found a suggestive asso-
ciation between PDE7B rs9494457 and POAG risk (P= 0.005). In
East Asians, we detected a nominal association of POAG with
TCF12 rs2593221 (P= 0.019). Except for rs149154973 near ELN,
all SNPs at novel loci showed consistent direction of effects across
all race/ethnicity groups, and no significant heterogeneity was
observed between race/ethnicity groups.
Replication in an independent external cohort. We then tested
the five lead SNPs representing each of the five novel loci for
replication in an independent, external meta-analysis in the
multiethnic UKB23, which includes 7 329 glaucoma cases and
169 561 controls from five race/ethnicity groups (European, East
Asian, South Asian, African British, and mixed ancestries)
(Supplementary Table 3). Three SNPs, including rs56117902 at
FMNL2, rs9494457 at PDE7B, and rs324794 near TMTC2,
replicated at Bonferroni significance (P= 7.9 × 10−5, 7.2 × 10−6,
and 6.8 × 10−3, respectively) with the same direction of effect
between the discovery association and replication sample
(Table 2). In addition, rs2593221 near TCF12 was associated at a
nominal level (P= 0.025). No data were available in UKB to test
SNP rs149154973 for replication.
Conditional and epistasis analyses. We next searched for addi-
tional genome-wide significant SNPs within a 2Mb window of
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the 12 lead SNPs (±1.0 Mb with respect to the lead SNP),
including those 12 lead SNPs identified in the discovery GERA
multiethnic GWAS analysis as covariates. We identified 3 addi-
tional SNPs with Bonferroni-level evidence of association with
POAG that appeared to be independent of the lead SNP signals
(P < 0.0001) at 3 loci (UCK2 on chromosome 1 (near TMCO1),
CDKN2B-AS1 on chromosome 9, and near SIX1 on chromosome
14) (Supplementary Table 4). We then conducted an epistasis
analysis of all pairs of lead SNPs in each race/ethnicity group, but
did not observe significant epistatic interactions between SNPs
after Bonferroni correction (P < 1.9 × 10−4= 0.05/(((12 × 11)/
2) × 4))).
Secondary and subgroup analyses. To further investigate whe-
ther the POAG susceptibility loci identified in this study influence
glaucoma susceptibility through their effect on IOP or indepen-
dently of IOP, we conducted three additional analyses. First, we
examined the association of lead SNPs at these loci with IOP,
which was assessed in the GERA cohort (see Methods). Of our 12
lead SNPs, 6 were associated at a Bonferroni level of significance
(P < 0.0014 for 12 SNPs in 3 analyses): rs7524755 at TMCO1;
rs56117902 at FMNL2; rs59521811 at AFAP1; rs9494457 at
PDE7B; rs2472493 near ABCA1; and rs9913911 at GAS7 (Sup-
plementary Table 5). Each of the POAG risk alleles was associated
with greater IOP.
We then examined the association of these SNPs in two POAG
subgroups: subjects with normal tension glaucoma (NTG)
compared to controls (743 NTG cases vs. 58 426 controls) and
subjects with high tension glaucoma (HTG) compared to controls
(4243 HTG cases vs. 58 426 controls). In the NTG analysis, of our
12 lead SNPs, 3 were associated at a Bonferroni level of
significance and each had more extreme odds ratios in
comparison to their association in the POAG GWAS:
rs6913530 near CDKN1A; rs10811645 at CDKN2B-AS1; and
rs35155027 in SIX1-SIX6 (Supplementary Table 5). In the HTG
analysis, all 12 lead SNPs were associated at Bonferroni
significance, consistent with this subset making up the majority
of the sample.
These results suggest that some of the POAG risk variants act
through their effect on IOP, while others do not. These findings
are consistent with previous studies reporting NTG associations
at CDKN2B-AS111,17. However, we did not confirm previous
NTG associations on 8q22 (top SNP rs284491[C], OR= 1.06, P
= 0.29) or 12q (rs2041895[C], OR= 1.04, P= 0.43)11,17 (Supple-
mentary Table 6).
Replication of previous POAG GWAS results. We also inves-
tigated in GERA the lead SNPs within 19 loci associated with
POAG at a genome-wide significance level or showing suggestive
evidence (P < 10−6) in previous studies8–18 (Supplementary
Table 7). Six of the 19 replicated at a genome-wide level of sig-
nificance in our GERA multiethnic meta-analysis (including
TMCO1 rs4656461, CDKN1A rs67530707, CDKN2B-AS1
rs4977756, ABCA1 rs2472493, SIX1/SIX6 rs10483727, and
GAS7 rs9897123) (Supplementary Table 7). Further, 7 additional
SNPs replicated at Bonferroni significance (P < 0.05/19= 0.0026),
and 1 (ATXN2 rs7137828) showed nominal evidence of associa-
tion (P= 0.0034). The previously reported14 rs199748604
(TRIM9-TMX1) reached nominal significance in African-Amer-
icans, but not in the other race/ethnicity groups.
In contrast, two SNPs (at NCKAP5 and PMM2), which
were reported with suggestive evidence of association with
POAG in previous studies of Asian individuals10,12, were
associated with POAG in neither the current GERA multiethnic
meta-analysis (P > 0.05), nor in the East Asian race/ethnicity
group. The absence of replication in our study is unlikely to be
due to a lack of statistical power, as we have estimated that
our study of 4986 cases and 58 426 controls (full GERA sample)
or 441 cases and 4034 controls (GERA East Asian race/ethnicity
group) had more than 80% power to detect the previously
reported effects for both SNPs rs7588567 and rs3785176.
We note that in our GERA sample, NCKAP5 rs7588567 had a
moderate imputation quality score r2 in non-Hispanic whites
(r2= 0.64), as well as in Hispanic/Latinos (r2= 0.63) and in
African-Americans (r2= 0.61). For this reason, rs7588567 was
excluded from the meta-analysis across the 4 race/ethnicity
Table 1 Characteristics of the POAG cases and controls from GERA cohort
Controls Cases
Total N (proportion that are cases) 58 426 4 986 (7.9%)
Age (years) Mean ± SD 69.7 ± 13.0 79.6 ± 9.4
Sex Women - N (proportion that are cases) 35 193 2 689 (7.1%)
Men - N (proportion that are cases) 23 233 2 297 (9.0%)
NTG cases N — 743
Controls with an OHTN diagnosis N 881 —
Median IOP Mean ± SD 14.9 ± 2.6 15.5 ± 2.9
Non-Hispanic white N (proportion that are cases) 48 065 3 836 (7.4%)
Age (years), mean ± SD 70.7 ± 12.5 80.5 ± 9.0
Sex, number of women/men 28 798/19 266 2 115/1 721
Hispanic/Latino N (proportion that are cases) 4 778 411 (7.9%)
Age (years) Mean ± SD 65.0 ± 14.4 75.5 ± 10.1
Sex, number of Women / Men 2 965/1 813 218/193
East Asian N (proportion that are cases) 4 034 441 (9.9%)
Age (years), mean ± SD 64.6 ± 14.4 76.6 ± 10.0
Sex, number of women/men 2 453/1 581 202/239
African-American N (proportion that are cases) 1 549 298 (16.1%)
Age (years), mean ± SD 66.7 ± 13.3 77.7 ± 9.3
Sex, number of women/men 976/573 154/144
N number, SD standard deviation, POAG primary open-angle glaucoma, NTG normal tension glaucoma, OHTN ocular hypertension, defined as participants who had a diagnosis of ocular hypertension but
have no diagnosis of any type of glaucoma, IOP intraocular pressure, Age age at last vision exam
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groups. Consistent with a previous study conducted in African-
American women14, DNAJC24 rs542340 and RBFOX1
rs192917960 were observed at a low frequency in African-
Americans, and were not polymorphic (minor allele frequency
(MAF) < 0.01%) in other race/ethnicity groups. So, these two
SNPs were excluded from the GERA multiethnic meta-analysis
and were not associated with POAG in the African-American
race/ethnicity group.
Array heritability estimates for POAG risk in GERA. We then
estimated the proportion of variance in POAG risk explained by
all SNPs on the genotyping array in the GERA non-Hispanic
white sample using GCTA25. Assuming a prevalence of 3% for
POAG2, we estimated an overall heritability of 0.26 (s.e.= 0.01).
Our results are consistent with a recent phenome-wide herit-
ability study conducted in the UKB and showing an overall
heritability estimate of 0.26 (s.e.= 0.06) for glaucoma7.
Variability in POAG risk explained. We then examined the
proportion of variance explained by previously known and newly
discovered SNPs in GERA. Previously reported SNPs explained
2.1% of the variation in POAG risk in non-Hispanic whites, 0.5%
in African-Americans, 2.0% in Hispanic/Latinos, and 0.3% in East
Asians. Newly identified variants increased the proportion of
variance explained to 3.0% in non-Hispanic whites, 3.1% in
African-Americans, 3.3% in Hispanic/Latinos, and 0.5% in East
Asians.
Lead glaucoma SNPs from UKB and replication in GERA. A
genome-wide analysis of glaucoma in the UKB sample identified
18 glaucoma-associated loci that achieved a genome-wide level of
significance, of which 9 have not been previously reported to be
associated with glaucoma (Table 3 and Supplementary Figure 2).
We then investigated the 9 lead SNPs representing each of the 9
independent novel loci for replication in the GERA POAG
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Fig. 1 Plots of POAG prevalence versus genetic ancestry in GERA. POAG prevalence is indicated on a color scale, standardized across groups, with warmer
colors indicating higher prevalence. Axes reflect the first two principal components of ancestry in each group. The phenotype distribution was smoothed
over the PCs (within the individuals in each respective figure), which were divided by their standard deviation for interpretability (see Methods). Human
Genome Diversity Project populations are plotted at their relative positions in each figure. Human Genome Diversity Project populations are presented in a
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analysis. Of the 9 novel glaucoma-associated SNPs, 6 replicated at
Bonferroni significance (P < 0.0055= 0.05/9) in the GERA meta-
analysis. These include rs56335522 near IKZF2 (P= 2.0 × 10−6),
rs34201102 in CADM2 (P= 2.1 × 10−5), rs9853115 near DGKG
(P= 2.2 × 10−5), rs76325372 in ANKH (P= 0.00045), rs2073006
in EXOC2 (P= 1.2 × 10−6), and rs55770306 in LMX1B (P=
0.00019) (Table 3). Two additional SNPs were associated in
GERA at a nominal level of significance (P < 0.05); all 9 SNPs had
the same direction of effect in GERA as in UKB.
Multiethnic meta-analysis of UKB and GERA. We then con-
ducted a multiethnic meta-analysis, combining the GERA and
UKB cohorts. We identified 47 loci at a genome-wide level of
significance, including an additional 24 novel loci (Fig. 2 and
Supplementary Table 8). These 24 loci will need to be validated in
an external replication sample to confirm their role in glaucoma
susceptibility.
Ancestry analysis adjusting for known risk SNPs. To determine
whether known POAG-associated loci explain the observed
associations of genetic ancestry with the risk of POAG, we
repeated the ancestry analysis within GERA Hispanic/Latinos,
East Asians, and African-Americans, including all newly and
previously identified POAG lead SNPs. The ancestry associations
were significantly attenuated in African-Americans, but only
slightly in the Hispanic/Latinos and slightly strengthened in East
Asians (Supplementary Table 9).
Gene expression in human ocular tissues. To prioritize genes for
further investigation, we identified the 95% credible set of var-
iants in each locus identified in either GERA or UKB (Supple-
mentary Data 1). We then examined expression levels in silico for
the 28 genes in the 24 unique loci that contained associated 95%
credible set variants in human ocular tissues using two publicly
available databases: the Ocular Tissue Database (OTDB)26; and
EyeSAGE27,28. According to OTDB, most of the identified genes
were expressed in most ocular tissues (Supplementary Table 10).
Gene expression in mouse ocular tissues. RGCs are the primary
cell type affected in glaucoma, however, treatments conferring
Table 3 Lead genome-wide significant SNP for each independent locus identified in the UK Biobank and replication in GERA
SNP Chr Pos Locus Alleles UKB discovery cohort GERA replication cohort
OR (95% CI) P OR (95% CI) P
rs2814471 1 165739598 TMCO1 C/T 1.39 (1.32–1.45) 7.5 × 10−44 1.34 (1.26–1.43) 2.0 × 10−20
rs56335522 2 213758234 near IKZF2 G/C 1.18 (1.11–1.25) 1.7 × 10−8 1.20 (1.11–1.29) 2.0 × 10−6
rs34201102 3 85137499 CADM2 A/G 1.11 (1.08–1.15) 6.1 × 10−10 1.10 (1.05–1.15) 2.1 × 10−5
rs9853115 3 186131600 near DGKG T/A 1.11 (1.07–1.15) 1.7 × 10−9 1.10 (1.05–1.14) 2.2 × 10−5
rs9330348 4 7883887 AFAP1 C/G 1.16 (1.12–1.20) 2.4 × 10−18 1.15 (1.10–1.20) 5.7 × 10−10
rs76325372 5 14837332 ANKH A/C 1.14 (1.09–1.18) 1.4 × 10−10 1.09 (1.04–1.14) 0.00045
rs2073006 6 637465 EXOC2 C/T 0.86 (0.82–0.90) 2.8 × 10−10 0.86 (0.81–0.92) 1.2 × 10−6
rs12699251 7 11679113 THSD7A A/G 0.90 (0.87–0.93) 1.5 × 10−9 0.95 (0.90–0.99) 0.017
rs6969706 7 116154831 CAV1/CAV2 G/T 0.90 (0.86–0.93) 8.4 × 10−9 0.91 (0.87–0.95) 9.6 × 10−5
rs2514884 8 108276873 ANGPT1 C/T 0.84 (0.80–0.88) 1.4 × 10−11 0.93 (0.87–0.98) 0.014
rs1333037 9 22040765 CDKN2B-AS1 C/T 0.84 (0.81–0.87) 2.4 × 10−23 0.77 (0.74–0.81) 2.9 × 10−29
rs2472493 9 107695848 near ABCA1 G/A 1.15 (1.12–1.19) 6.3 × 10−17 1.17 (1.12–1.22) 1.2 × 10−13
rs55770306 9 129388033 LMX1B C/A 0.86 (0.83–0.90) 5.5 × 10−14 0.90 (0.85–0.95) 0.00019
rs2274224 10 96039597 PLCE1 G/C 0.91 (0.88–0.94) 3.1 × 10−8 0.96 (0.92–1.00) 0.058
rs12806740 11 120203628 TMEM136 G/A 0.90 (0.87–0.93) 3.8 × 10−9 0.93 (0.89–0.97) 0.0017
rs34935520 14 61091401 SIX1/SIX6 G/A 1.14 (1.10–1.17) 3.6 × 10−13 1.17 (1.12–1.22) 1.8 × 10−12
rs9913911 17 10031183 GAS7 A/G 1.17 (1.13–1.21) 2.2 × 10−17 1.22 (1.17–1.28) 1.5 × 10−18
rs58714937 22 19856710 near TXNRD2 C/T 1.15 (1.10–1.21) 8.3 × 10−9 1.15 (1.09–1.23) 2.6 × 10−6
P-values in bold achieved genome-wide level of significance (P < 5 × 10−8); loci that are underlined are novel
SNP single-nucleotide polymorphism, Chr chromosome, Pos position, OR odds ratio
Table 2 Lead genome-wide significant SNP for each independent locus identified in the GERA discovery GWAS of POAG
SNP Chr Pos Locus Alleles GERA discovery cohort UKB replication cohort
OR (95% CI) P OR (95% CI) P
rs7524755 1 165694897 TMCO1 T/C 1.35 (1.27–1.44) 1.6 × 10−21 1.37 (1.31–1.43) 8.3 × 10−41
rs56117902 2 153304730 FMNL2 A/C 0.88 (0.84–0.92) 1.0 × 10−8 0.93 (0.90–0.97) 7.3 × 10−5
rs59521811 4 7909772 AFAP1 T/C 0.86 (0.82–0.90) 1.2 × 10−11 0.86 (0.83–0.89) 9.8 × 10−17
rs6913530 6 36598209 near CDKN1A G/A 0.86 (0.82–0.90) 2.3 × 10−9 0.98 (0.95–1.02) 0.44
rs9494457 6 136474794 PDE7B T/A 1.16 (1.11–1.22) 3.0 × 10−11 1.08 (1.05–1.12) 7.4 × 10−6
rs149154973 7 73322211 near ELN TG/T 0.70 (0.62–0.79) 3.9 × 10−9 NA NA
rs10811645 9 22049656 CDKN2B-AS1 G/A 0.77 (0.74–0.80) 2.8 × 10−32 0.86 (0.83–0.89) 1.0 × 10−18
rs2472493 9 107695848 near ABCA1 G/A 1.17 (1.12–1.22) 1.2 × 10−13 1.15 (1.12–1.19) 6.3 × 10−17
rs324794 12 83946450 near TMTC2 G/T 0.87 (0.83–0.91) 6.1 × 10−10 0.95 (0.92–0.99) 6.8 × 10−3
rs35155027 14 61095174 SIX1/SIX6 G/C 1.17 (1.12–1.23) 1.1 × 10−12 1.13 (1.10–1.17) 6.2 × 10−13
rs2593221 15 57501414 TCF12 A/G 0.86 (0.82–0.90) 8.5 × 10−10 0.96 (0.92–0.99) 0.025
rs9913911 17 10031183 GAS7 A/G 1.22 (1.17–1.28) 1.5 × 10−18 1.17 (1.13–1.21) 2.2 × 10−17
P-values in bold achieved genome-wide level of significance (P < 5 × 10−8); loci that are underlined are novel
SNP single-nucleotide polymorphism, Chr chromosome, Pos position, OR odds ratio, NA not available
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cytoprotection to RGCs have not been identified due to limita-
tions in our understanding of glaucomatous degeneration. Sus-
ceptibility factors both intrinsic to RGCs and the cells that
surround the RGC axons in the optic nerve head, including
astroglia, microglia, and endothelial cells are thought to be critical
mediators of the degenerative process. We first determined
whether genes in the associated loci serve as susceptibility factors
contributing to glaucomatous neurodegeneration. To this end, we
assessed the expression of each gene implicated in the 95%
credible sets and that also has a mouse homolog in the RGCs or
the optic nerve head tissue of the DBA/2J (D2) inherited mouse
model of glaucoma (Supplementary Data 1—see Methods). Spe-
cifically, we utilized previously published RNA-sequencing data-
sets from RGCs isolated from D2 retina29, and the microarray
gene expression datasets of the D2 optic nerve head, a critical
injury site mainly comprising of RGC axons, astroglia, microglia,
and blood vessels30. These datasets were compared to their
respective age- and sex-matched genetic controls (D2-Gpnmb+, a
strain that does not develop high IOP or glaucoma)29. We
specifically assessed the expression of 24 genes in 4 distinct
glaucoma groups (grouping performed by hierarchical clustering
(HC) based on gene expression patterns) or various stages
based on disease severity (see Methods) compared to the control
group.
Based on expression profiling of the RGCs, 12 of the genes
were differentially expressed (at a false discovery rate (FDR) q <
0.05) in one or more of the glaucoma groups compared to
controls (Supplementary Figure 4a). These included Angpt1, Ank,
Cadm2, Fmnl2, Plce1, Thsd7a, and Tmtc2 at the novel POAG/
glaucoma loci identified in the current study. Seven of the 12
differentially expressed genes show moderate to high expression
in mouse RGCs (i.e., at a normalized count per million of >100),
including Afap1, Ank, Cadm2, Gas7, Thsd7a, Tmem136, and
Tmtc2 (Supplementary Figure 4b). Based on the gene profiling in
the optic nerve head tissue, Cadm2, Cdkn2b, and Tmtc2 exhibit
altered expression very early and across all stages of glaucoma
(early to severe, Supplementary Table 11). Thus, expression
profiling has facilitated identification of initial set of genes that
warrant further interrogation to determine their potential role in
modulating susceptibility of RGC cells and their axons in
response to high IOP.
Trabecular meshwork modifications due to FMNL2 silencing.
We hypothesized that FMNL2, a gene in one of the novel POAG-
associated loci that is also associated with IOP31, supports tra-
becular meshwork (TM) function relevant to aqueous humor
outflow regulation. FMNL2 belongs to the formin-related family
of proteins that acts as a downstream effector of CDC42 (Rho
family member) regulating the shape and movement of cells
through its effect on actin nucleation and elongation32,33. Reg-
ulation of actin cytoskeletal dynamics, including formation of
actin stress fibers, is critical for contractile properties of cells. The
outflow of aqueous humor through the ocular drainage system is
dependent on the contractile properties of TM cells34,35. Here we
examined whether FMNL2 contributes to the assembly of actin
stress fibers, and induces cell morphological changes of TM cells,
a process critical for supporting contractile activity.
To this end, cells from a HTM cell line were transfected with
siRNAs to suppress the expression of FMNL2. We confirmed that
siRNAs targeting FMNL2 caused a significant knockdown of
FMNL2 expression, but did not alter the expression of a related
gene FMNL3, a paralog of FMNL2 (Fig. 3a). Our results show that
serum-starved HTM cells transfected with FMNL2 siRNA
exhibited a refractile morphology, appearing deformed or
rounded, whereas cells transfected with control siRNA, exhibited
a more flattened or spread morphology (Fig. 3b, c and
Supplementary Figure 5). Moreover, in the serum-starved cells,
the actin stress fibers, visualized by phalloidin staining of actin
filaments, were disrupted in both the control or FMNL2 siRNA-
transfected HTM cells (Fig. 3b and Supplementary Figure 5).
Overall, our data suggest that knockdown of FMNL2 induces
changes in HTM cell morphology likely due to its effect on actin
stress fiber assembly.
Genetic background influenced the effect of Lmx1b mutations.
Mutations in LMX1B are previously established to cause nail-
patella syndrome (NPS), a rare developmental disorder char-
acterized by skeletal abnormalities, as well as kidney and eye
defects36,37. The presentation of glaucoma in NPS patients is
variable; some patients develop a phenotype resembling open-
angle glaucoma, while in others, glaucoma is accompanied by
developmental defects of the ocular anterior segment, including
cataracts and abnormalities of the iris and cornea37,38. We have
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previously characterized a mouse model carrying a dominant
missense mutation in Lmx1b (Lmx1bV265D) that develops ele-
vated IOP and glaucoma along with severe ocular developmental
anomalies39. Here, to functionally evaluate whether Lmx1b
mutations can cause glaucoma without obvious developmental
anomalies, we studied the effects of the same mutation on two
different genetic backgrounds, and a new mutation that has not
previously been functionally characterized. Specifically, the
Lmx1bV265D allele was backcrossed onto the C57BL/6J (B6) and
129S6/SvEvTac (129) strain backgrounds; the Lmx1bQ82X allele
was present on a DBA/2J.Gpnmb(wt) (D2) background.
Slit lamp-based clinical eye examination showed that the B6
mutant mice exhibit a severe developmental phenotype char-
acterized by malformed eccentric pupils, irido-corneal strands,
corneal haze, and corneal scleralization (Fig. 4a). The
developmental phenotype on a 129 background was much
milder, and mainly limited to mild pupillary abnormalities in
about half of the mice. No major developmental abnormalities
were detected in D2 mice with the Lmx1bQ82X allele (focal corneal
keratopathy is an unrelated strain characteristic of D2 mice that is
frequently present in both wild-type (WT) and mutant mice).
Further, with age, high IOP often results in a more dilated pupil
in D2.Lmx1bQ82X/+ mice. The B6.Lmx1bV265D/+ and D2.
Lmx1bQ28X/+ mice were highly susceptible to developing
glaucomatous nerve damage (Fig. 4b, c). Finally, Lmx1b
mutations induced elevated IOP in all three strain backgrounds
(Fig. 4d, e). IOP is highly variable in the B6.Lmx1bV265D/+, which
is possibly caused by a variety of reasons. One possible
explanation for the spread of IOPs is due to Lmx1b mutants
exhibiting abnormal corneas that are often stretched and
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sometimes perforate. This is a likely explanation, especially
considering that B6 Lmx1b mutants have the most severely
affected corneas as well as the lowest IOPs. Additionally,
variability in IOP may result from stochastic variation in
developmental consequences resulting from the Lmx1b mutation.
As precedents, various mutant genes that affect development of
ocular drainage structures also variably result in maldevelopment
of the ciliary body40,41. Overall, our data demonstrate that genetic
background has a profound impact on the manifestation of
glaucoma-related phenotypes caused by mutations in Lmx1b.
Importantly, the presence of high IOP or glaucoma in eyes
without major developmental anomalies further supports a role of
LMX1B in the pathogenesis of OHTN and glaucoma in the
general population.
Discussion
In the large, ethnically diverse GERA cohort, we discovered 5
novel genome-wide significant POAG loci, of which 3 (FMNL2,
PDE7B, and near TMTC2) replicated at a Bonferroni level of
significance in the UKB cohort. We also investigated 9 novel
glaucoma-associated loci from UKB in GERA, and 6 of the novel
loci replicated at Bonferroni significance (near IKZF2, CADM2,
near DGKG, ANKH, EXOC2, and LMX1B). Further, a multiethnic
meta-analysis combining GERA and UKB identified an additional
24 novel loci that await validation in an external replication
cohort. Our results also confirmed the association of variants with
POAG in 14 previously reported loci, including TGFBR3,
TMCO1, AFAP1, FOXC1, GMDS, CDKN1A, CAV1/CAV2,
CDKN2B-AS1, ABCA1, ARHGEF12, ATXN2, SIX1/SIX6, GAS7,
and TXNRD2.
We recently reported31 that variants at FMNL2 are associated
with variation in IOP levels. Here we have demonstrated that
variants at FMNL2 are also associated with the risk of POAG,
with the higher IOP level allele associated with an increased risk
of POAG. Therefore, FMNL2 likely contributes to glaucoma
susceptibility through its effect on elevated IOP. Consistent with
this suggested mechanism of action, we showed that FMNL2
participates in the assembly of actin stress fibers and induction of
morphological changes of HTM cells. Actin stress fibers are
bundles of contractile actomyosin that play an important role in
mediating cellular adhesion and morphogenesis. The small
GTPases RhoA, Rac1, and Cdc42 mainly regulate dynamics of
actin assembly and disassembly. In general, RhoA is thought to
40
30
20
10
0
40
30
20
10
0
IO
P 
(m
m 
Hg
)
IO
P 
(m
m 
Hg
)
*** ***
SEV
MOD
NO
D2
.Lm
x1
bQ
82X
/+
D2
.Lm
x1
b+
/+
B6
.Lm
x1
bV
26
5D
/+
B6
.Lm
x1
b+
/+
B6
.Lm
x1
b+
/+
B6
.Lm
x1
bV
26
5D
/+
12
9.L
mx
1b
+/+
12
9.L
mx
1b
V2
65
D/+
D2
.Lm
x1
b+
/+
D2
.Lm
x1
bQ
82X
/+
B6
.Lm
x1
b+
/+
B6
.Lm
x1
bV
26
5D
/+
12
9.L
mx
1b
+/+
12
9.L
mx
1b
V2
65
D/+
D2
.Lm
x1
b+
/+
D2
.Lm
x1
bQ
82X
/+
100%
75%
50%
25%
0%
Pe
rc
en
ta
ge
 n
er
ve
s 
at
e
a
ch
 d
am
ag
e 
le
ve
l
****** **
Highest k-means cluster
WT
WT
V
V265D/+
Q82X/+
*
V
CuppedNot cupped
RNFL
GCL
INL
ONL
OPL
IPL
Wild type
*
B6.Lmx1bV265D/+ 129.Lmx1bV265D/+ D2.Lmx1bQ82X/+
RNFL
GCL
INL
ONL
OPL
IPL
a b
c d e
Fig. 4 Lmx1b can induce high IOP and glaucoma in developmentally normal eyes. a Slit lamp examination of control B6.Lmx1b+/+, B6.Lmx1bV265D/+, 129.
Lmx1bV265D/+, and D2.Lmx1bQ82X/+ at 9 months of age. All D2 mice were wild-type (WT) for Gpnmb. Lmx1b WT eyes on all backgrounds were
developmentally normal and so only the B6 controls are shown. B6 mutant mice have a severe developmental phenotype, involving severely malformed
eccentric pupils, irido-corneal strands, corneal haze, and corneal scleralization (upper panels). These developmental phenotypes are much milder or absent
in mutants on the other backgrounds, with about 50% of mutants on the 129 background having very mild pupillary abnormalities. No mutants on the D2
background had developmental abnormalities. In WT eyes, we can distinguish a very shallow anterior chamber, and, as a result of IOP elevation, the
chamber depth increases to different degrees in mutants on each genetic background (lower panels). N≥ 30 for each group. b Optic nerve cupping
(asterisks) and retinal nerve fiber layer (RNFL) thinning (arrowheads), two hallmarks of glaucoma, was present in mutant eyes with severely affected optic
nerves but not in WT eyes (10 months’ B6 H&E-stained sections, top panels, and 13 months’ D2 eyes SD-OCT images shown, bottom panels). Scale bar=
200 μm for H&E-stained images and 100 μm for SD-OCT images. V optic vessel, GCL ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer,
OPL outer plexiform layer, ONL outer nuclear layer. c Nerve damage plots for 10-month B6 and 14.5-month-old D2 eyes N≥ 24 for each group, Fisher’s
exact test: ***P < 0.001. d A proportion of mice carrying the Lmx1b mutations exhibit elevated IOP on all three strain backgrounds as compared to their
respective controls. IOP values are clustered within each group using k-means clustering (k= 3), blue= low IOP cluster, black= average IOP cluster, red
= high IOP cluster. N≥ 24 for each group, 6 months old shown. e IOP values in the high IOP clusters are significantly elevated in Lmx1b mutant mice
compared with WT controls. Statistical analysis was done using a one-way ANOVA followed by Tukey’s HSD, ***P < 0.001, **P < 0.01
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04555-4
8 NATURE COMMUNICATIONS |  (2018) 9:2278 | DOI: 10.1038/s41467-018-04555-4 |www.nature.com/naturecommunications
directly promote formation of actin stress fibers through its
downstream effector, Rho-associated protein kinase (ROCK)42.
Inhibitors of ROCK have been reported to disrupt actin stress
fiber formation and modulate contractile activity of TM cells,
thereby increasing aqueous outflow and lowering IOP35,43.
Recently, an ophthalmic solution consisting of netarsudil
0.02% [Rhopressa®], a ROCK inhibitor has been approved
in the United States for the reduction of elevated IOP in patients
with POAG44. Another ophthalmic solution, ripasudil hydro-
chloride hydrate [Glanatec®], which is also a ROCK inhibitor,
has been approved in Japan for the treatment of glaucoma
and OHTN45. The small GTPase Cdc42 acts through its
downstream mediators FMNL2 and FMNL3 to indirectly regulate
the organization of the stress fibers by inducing formation of
filopodia and promoting cell migration33. The function of
FMNL2 in non-motile cells is not well defined. Our findings
suggest a role of FMNL2 in the assembly of actin stress fibers and
for inducing morphological changes of TM cells, functions inte-
gral to the regulation of aqueous outflow and maintenance of
normal IOP. The effect of FMNL2 on actin stress fiber formation
is likely to be indirect via its influence on cell adhesion-based
mechanisms that generate cellular tension and leading to RhoA
activation32,46.
We also identified a new region associated with POAG at
PDE7B on chromosome 6. PDE7B encodes phosphodiesterase
(PDE) 7B, a cAMP-specific PDE member of the cyclic nucleotide
PDE family. The concentration of cAMP, a key second messenger
of several biological processes is tightly regulated, by balancing its
synthesis by adenylyl cyclases and its degradation by cAMP-
specific PDEs. Pharmacologic inhibition or genetic inactivation of
soluble adenylyl cyclase (sAC) in mice suppresses aqueous humor
outflow, leading to elevated IOP47. Additionally, activation of
sAC has been shown to elevate cAMP levels in RGCs, a critical
step necessary for promoting RGC survival48. Thus, PDE7B
through its effect on the regulation of cAMP levels may con-
tribute to aqueous humor outflow or support RGC survival,
functions that have important consequences in the pathogenesis
of glaucoma.
The mechanisms that render RGCs susceptible to glaucoma-
tous damage are largely unknown. Various insults including
ischemia, excitotoxicity, inflammation, axonal injury, and glial
activation have been proposed to contribute to RGC damage49.
Degenerative programs both intrinsic and extrinsic to RGCs and
their axons have been suggested to contribute to glaucomatous
neurodegeneration49,50. Here we have identified a set of genes in
POAG-associated loci whose expression is altered in the RGCs
(e.g., Ank, Cadm2, and Six6) and the optic nerve head (e.g.,
Cadm2 and Cdkn2b) in a mouse model of glaucoma. Some of
these expression changes occur very early, even before their eyes
show any signs of RGC loss, suggesting some of these genes may
play a critical role in the pathogenesis of glaucomatous neuro-
degeneration. Future studies will determine if the identified genes
are part of the pathways conferring susceptibility to glaucomatous
neurodegeneration.
Our study also identified a new region on chromosome 12
associated with POAG, near TMTC2. The TMTC2 locus has been
previously reported to be associated with POAG in a Japanese
population51, with a different lead SNP (rs7961953), however,
this association did not reach a genome-wide level of significance,
possibly due to limited sample size (total of 827 Japanese POAG
patients and 748 control subjects without glaucoma)51. More
recently, a study of optic disc morphology identified genome-
wide significant associations between variants near TMTC2 and
optic disc size and cup area52. Genetic variation in the TMTC2
locus may contribute to glaucomatous neurodegeneration
through its effect on optic nerve morphology.
Further, we identified LMX1B as a glaucoma susceptibility
locus. LMX1B gene encodes LIM (Lin-1, Isl-1, and Mec-3)-
homeodomain transcription factor 1 beta, and rare deleterious
mutations in LMX1B cause NPS, with glaucoma being one of the
manifestations of the syndrome36,53. Haploinsufficiency of
LMX1B is generally accepted to cause NPS, but dominant nega-
tive effects are also possible37,39. Substantial phenotypic varia-
bility occurs among NPS patients with glaucoma occurring in
about 30% of these patients36,37. In many of these patients, the
glaucoma phenotype appears similar to open-angle glau-
coma37,38, with no obvious structural abnormalities in the ante-
rior segment. In other patients, anterior segment developmental
defects, including cataracts and abnormalities of the iris and
cornea, are present, leading to the suggestion that LMX1B
mutations contribute to the spectrum of glaucomas resulting
from developmental defects37. Our findings demonstrate strong
modifying effects of genetic background on ocular phenotypes
induced by Lmx1b mutations, such that the mutations cause
elevated IOP and glaucomatous nerve damage both in the pre-
sence and in the absence of obvious ocular developmental
anomalies. This demonstration that Lmx1b mutations result in
elevated IOP and glaucomatous nerve damage in eyes without
developmental defects, supports the notion that LMX1B affects
the risk of glaucoma in the absence of obvious developmental
anomalies in human eyes.
Finally, our study reports differences in the prevalence of
POAG across race/ethnicity groups, consistent with previous
reports54. Within Hispanic/Latinos, East Asians, and African-
Americans, the risk of POAG was associated with genetic
ancestry. Specifically, a greater risk of POAG was associated with
higher Native American (compared to European) ancestry among
Hispanic/Latinos, higher northern East Asian (compared to
southern East Asian) ancestry among East Asians, and higher
African (compared to European) ancestry among African-
Americans. After taking into account the effect of newly and
previously identified SNPs, the ancestry association in African-
Americans was attenuated, the association of ancestry in His-
panic/Latinos was nearly unchanged, and in East Asians the
association with ancestry became slightly stronger. Thus, the
identified POAG loci can explain some of the ancestry effects in
African-Americans, but not Hispanic/Latinos and East Asians,
suggesting that additional POAG risk loci that correlate with
ancestry within East Asian and Hispanic populations remain to
be discovered.
We recognize several potential limitations of our study. First,
glaucoma diagnoses in UKB (our replication sample) were based
on self-reported data, and the subtypes of glaucoma were
unspecified, which may result in underestimates of the effects of
individual SNPs due to phenotype misclassification. As a con-
sequence, our replication analysis based on the UKB was likely
underpowered relative to its sample size. However, in UKB, the
proportion of glaucoma cases was relatively close to that reported
for the global prevalence of glaucoma for population aged 40–80
years1,2. Second, the GERA non-Hispanic white participants were
older on average than the GERA participants from the other race/
ethnicity groups (Hispanic/Latino, East Asian, and African-
American). This could explain the similar proportion of POAG
cases in non-Hispanic whites and Hispanic/Latinos in our study,
as advancing age has been shown to be a major risk factor for
POAG1,2. Third, in our study, we note that the African-American
subgroup has the smallest sample size compared to the other
race/ethnicity groups, potentially limiting statistical power to
detect some SNP associations. We note, however, that we did
observe nominally significant associations with several previously
reported and newly identified POAG risk loci in this group.
Finally, although investigating all implicated genes in the current
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study would be of great interest, we restricted our functional
investigations to two genes (FMNL2 and LMX1B) because they
were implicated in the 95% credible set, were novel loci, replicated
in an independent cohort, and resources were available for
functional characterization. Further, the use of the transformed
human NTM-5 cells as opposed to primary HTM cells to study
FMNL2 function represents another limitation of the study.
In conclusion, we identified a total of 9 novel loci associated
with the risk of POAG/glaucoma at a genome-wide significance
level that replicated in an independent sample. Our multiethnic
meta-analysis combining GERA and UKB identified an additional
24 novel loci that await validation. These loci explain some, but
not all, of the observed effect of genetic ancestry on POAG sus-
ceptibility. Our expression analyses of RGCs and optic nerve head
tissue suggest that several newly identified candidate genes may
play a role in glaucomatous neurodegeneration. Finally, func-
tional characterization of FMNL2 and LMX1B points to a
mechanistic effect on IOP levels, which supports their role as
glaucoma risk genes.
Methods
GERA population. We report a GWAS of glaucoma in 4 986 cases and 58 426
controls from the GERA cohort. The GERA cohort consists of 110 266 adults who
consented to participate in the Research Program on Genes, Environment, and
Health, established for members of the Kaiser Permanente Medical Care Plan,
Northern California Region (KPNC)55,56. The Institutional Review Board of the
Kaiser Foundation Research Institute has approved all study procedures.
Case and control definition. All GERA subjects included in this study had valid
IOP measures, as previously described31. Briefly, non-numeric entries for IOP,
extreme values (≤5 and >60 mmHg), and measurements taken on a single eye were
removed. Further, IOP measurements that were taken after initial prescription of
IOP-lowering medications were excluded to avoid values influenced by treatment.
Because IOP-lowering medications are almost always prescribed before IOP-
lowering surgical interventions (i.e., laser trabeculoplasty, trabeculectomy, tube
shunt procedures, etc.), we did not remove subjects who had these surgical
interventions. Patients eligible for inclusion were identified from clinical diagnoses
captured in the KPNC electronic health record (EHR) system. These clinical
diagnoses were recorded in the EHR system as International Classification of
Diseases, Ninth Revision (ICD-9) diagnosis codes. We defined glaucoma cases as
having at least: (1) two diagnoses of POAG (ICD-9 codes 365.01, 365.1, 365.10,
365.11, and 365.15); or (2) two diagnoses of NTG (ICD-9 code 365.12); or (3) one
diagnosis of POAG and one diagnosis of NTG. In all cases, at least one of the
diagnoses was made by a Kaiser Permanente ophthalmologist. Further, the cases
did not have any diagnosis of other subtypes of glaucoma (e.g., pseudoexfoliation,
pigmentary, or PACG; ICD-9 codes 365.52, 365.13, and 365.2, respectively). After
excluding subjects who have one or more diagnosis of any type of glaucoma (ICD-9
code, 365.xx), our control group included all the non-cases. Subjects who had no
diagnosis of any type of glaucoma (any ICD-9 code 365.xx other than 365.04) but
did have a diagnosis of OHTN (ICD-9 code 365.04), were included as controls. In
total, 4986 POAG (including 743 NTG cases and 4 243 HTG cases) and 58 426
controls from GERA were included in this study.
Genotyping and quality control and imputation. GERA individuals’ DNA
samples were extracted using Oragene kits (DNA Genotek Inc., Ottawa, ON,
Canada) at KPNC and genotyped at the Genomics Core Facility of UCSF. DNA
samples were genotyped at over 665 000 genetic markers on four race/ethnicity-
specific Affymetrix Axiom arrays (Affymetrix, Santa Clara, CA, USA) optimized
for European, Latino, East Asian, and African-American individuals57,58. We
performed genotype quality control (QC) procedures for the GERA samples on an
array-wise basis56. Briefly, we included genetic markers with initial genotyping call
rate ≥ 97%, genotype concordance rate > 0.75 across duplicate samples, and allele
frequency difference ≤ 0.15 between females and males for autosomal markers.
Approximately 94% of samples and over 98% of genetic markers assayed reached
QC procedures. Moreover, genetic markers with genotype call rates < 90% were
excluded, as well as genetic markers with a MAF < 1%.
We also performed imputation on an array-wise basis. Following the pre-
phasing of genotypes with Shape-IT v2.r7271959, we imputed genetic markers from
the cosmopolitan 1000 Genomes Project reference panel (phase I integrated release;
http://1000genomes.org) using IMPUTE2 v2.3.060.We used the information r2
from IMPUTE2 as a QC parameter, which is an estimate of the correlation of the
imputed genotype to the true genotype61. Genetic markers with an imputation r2 <
0.3 were removed, and we restricted to markers that had a minor allele count ≥ 20.
GWAS analysis and covariate adjustment. We first analyzed each of the four
self-reported race/ethnicity groups (non-Hispanic whites, Hispanic/Latinos, East
Asians, and African-Americans) separately. We ran a logistic regression of POAG
and each SNP using PLINK62 v1.9 (www.cog-genomics.org/plink/1.9/) with the
following covariates: age; sex; and ancestry principal components (PCs). We
modeled data from each genetic marker using additive dosages to account for the
uncertainty of imputation63.
Eigenstrat64 v4.2 was used to calculate the PCs on each of the 4 race/ethnicity
groups, and subjects were included for analyses in their self-reported group, as
previously described55. We included as covariates the top 10 ancestry PCs for the
non-Hispanic whites, whereas we included the top 6 ancestry PCs for the 3 other
race/ethnicity groups. To adjust for genetic ancestry, we also included the
percentage of Ashkenazi (ASHK) ancestry as a covariate for the non-Hispanic
white race/ethnicity group analysis55. The ASHK proportion was extracted from
the initial European PC analysis, where individuals of European and ASHK
ancestries were run together to produce eigenvectors. The clusters resulting from
this were re-classified as 0.0, 0.5, 0.75, and 1.0 ASHK (by drawing grids in the
PC1–PC2 space). A full description of the ancestry analyses is provided in Banda
et al.55.
GERA meta-analysis of POAG. We then undertook a GERA meta-analysis of
POAG to combine the results of the four race/ethnicity groups using the R65
(https://www.R-project.org) package “meta”. We calculated fixed effects summary
estimates for an additive model. We also estimated heterogeneity index, I2
(0–100%) as well as P-value for Cochrane’s Q statistic among groups. For each
locus, we defined the top SNP as the most significant SNP within a 2Mb window,
and novel loci were defined as those that were located over 1 Mb apart from any
previously reported locus.
Plots of POAG prevalence vs. genetic ancestry. To visualize the glaucoma
distribution by the ancestry PCs, we created a smoothed distribution of each
individual i’s glaucoma phenotype using a radial kernel density estimate weighted
on the distance to each other jth individual, ∑jϕ({d(i,j)/maxi′,j′[d(i′,j′)] × k)}), where
ϕ(.) is the standard normal density distribution, k is the smooth value (5 for non-
Hispanic whites; and 15 for East Asians, Hispanic/Latinos, and African-Amer-
icans), and d(i′,j′) is the Euclidean distance based on the first two PCs. Race/
ethnicity and/or nationality subgroup labels were derived from GERA or the
Human Genome Diversity Project for visual representation of different groups55.
Secondary and subgroup analyses in GERA. As a secondary analysis, we also
assessed the associations between the 12 POAG-associated loci identified in GERA
and IOP. IOP values were entered by clinicians at each vision encounter and were
captured in the EHRs31. To measure IOP in KPNC ophthalmology practices, the
major standard equipment used is a Goldmann applanation tonometer (Haag-
Streit, Bern, Switzerland), followed by a non-contact tonometer (Nidek TonoRef
II), a Tono-Pen XL, an iCare rebound tonometer (Tiolat, Helsinki, Finland) and
other equipment, such as pneumotonometers. We evaluated individual’s mean IOP
from both eyes for each visit, and the individual’s median of the mean across all the
visits was used for analysis. A linear regression of IOP and each SNP was per-
formed using PLINK v1.9 with age, sex, and ancestry PCs as covariates.
For the NTG and HTG analyses, we divided the POAG group into those
subjects who met criteria for NTG (NTG group) and those subjects who met
criteria for POAG but not NTG (HTG group). For the 373 subjects who met
criteria for both POAG and NTG, an ophthalmologist (R.M.) chart reviewed each
subject to categorize them into either group.
Conditional association analyses were conducted to identify additional
independent SNPs at each locus by including all the 12 lead SNPs identified in the
GERA multiethnic meta-analysis as covariates in the regression model. We
evaluated whether any additional SNPs within a 2Mb window (±1.0 Mb with
respect to the original top SNP) achieved genome-wide significance. Associations
that replicate at a Bonferroni-corrected significance threshold of 0.05/500= 0.0001
(corresponding to an estimate of ~500 independent SNPs per locus for 2 Mb
interval surrounding each of our original signals)66 are reported. Finally, we
conducted an epistasis analysis of all pairs of top SNPs in the four GERA race/
ethnicity groups. For this analysis, a Bonferroni-corrected significance threshold of
0.05/264= 1.9 × 10−4 (accounting for the number of SNP pairs tested (12 × 11)/2,
and for the four race/ethnicity groups) was applied.
Replication analysis of previously reported SNPs in GERA. To assess whether
the 19 previously described POAG-associated loci replicated in the GERA cohort,
we tested 19 statistically independent top SNPs previously described to be asso-
ciated at a genome-wide level of significance (N= 17) or showing suggestive evi-
dence (N= 2) of association (P < 10−6)8–18. We reported a nominal significance
level of 0.05 and a more stringent multiple testing correction accounting for the
number of variants tested (Bonferroni-corrected alpha level of 0.0026 (=0.05/19)).
GWAS heritability estimates and variance explained. SNP-based heritability
estimates were estimated for POAG using the GCTA software25. GCTA software
computes the phenotypic variance explained by all analyzed genetic markers in the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04555-4
10 NATURE COMMUNICATIONS |  (2018) 9:2278 | DOI: 10.1038/s41467-018-04555-4 |www.nature.com/naturecommunications
genome by restricted maximum likelihood reached using expectation maximiza-
tion. The analysis was restricted to autosomal markers, and we applied a genetic
relationship matrix cutoff of 0.025. For statistical power purposes, the SNP-based
heritability estimates analysis was conducted in the the non-Hispanic white race/
ethnicity group, which is the largest group of individuals in GERA.
UK Biobank. To test the five novel GERA genome-wide significant SNPs for
replication, we evaluated associations in the multiethnic UKB23, which consisted of
7 329 glaucoma (subtype unspecified) cases and 169 561 controls from five race/
ethnicity groups (European, East Asian, South Asian, African British, and mixed
ancestries) (Supplementary Table 3). Imputation to the Haplotype Reference
Consortium (HRC) has been described (www.ukbiobank.ac.uk), and imputation at
a few non-HRC sites (for replication) was done pre-phasing with Eagle67 and
imputing with Minimac368 with the 1000 Genomes Project Phase I. The glaucoma
phenotype was assessed through a touchscreen self-report questionnaire completed
at the Assessment Centre, via the question “Has a doctor told you that you have
any of the following problems with your eyes?”, and cases were defined as those
reporting “glaucoma.” The control group included the non-cases and excluded
subjects who reported “Prefer not to answer” or “Do not know.”
In silico analyses. To provide a list of candidate genes for follow-up functional
evaluation, a Bayesian approach (CAVIARBF)69 was used, wich is publicly avail-
able at https://bitbucket.org/Wenan/caviarbf. This approach has been successfully
used in previous studies66,70. For each of the associated signals, we computed each
variant’s capacity to explain the identified signal within a 2 Mb window (±1.0 Mb
with respect to the original top variant) and derived the smallest set of variants that
included the causal variant with 95% probability (95% credible set). A total of 1 098
variants in 28 annotated genes were included in these 24 credible sets (Supple-
mentary Data 1).
We evaluated expression of the genes that contained associated 95% credible set
variants in human ocular tissues using two publicly available databases: the
OTDB26; and EyeSAGE27,28 publicly available at https://genome.uiowa.edu/otdb/
and http://neibank.nei.nih.gov/EyeSAGE/index.shtml, respectively. The OTDB
consists of gene expression data for 10 eye tissues from 20 normal human donors,
and the gene expression is described as Affymetrix Probe Logarithmic Intensity
Error (PLIER) normalized value26.
Gene expression in DBA/2J mice ocular tissues. RNA-seq was performed on
RGCs isolated from the retina of either 9-month-old D2 mice or a genetically
matched control strain (substrain of D2 mice, D2-Gpnmb+ that do not develop
high IOP/glaucoma)29. D2 and D2-Gpnmb+ mice used for the gene expression
studies were from the The Jackson Laboratory, and experimental mice were all 9-
month-old females (Gene Expression Omnibus accession number GSE90654). The
D2 mouse is an age-dependent model of OHTN/glaucoma that closely mimics
human pigmentary glaucoma71. In the D2 mouse, mutations in two alleles
(GpnmbR150X and Tyrp1b) drive progressive iris pigment dispersion and iris stro-
mal atrophy that blocks and damages the ocular drainage tissue, leading to elevated
IOP72. In our colony, D2 mice begin to exhibit high IOP around 6 months of age,
and by 9 months of age (the age that we profiled) the majority of eyes have
undergone periods of elevated IOP but are yet to develop any detectable RGC
degeneration. Following this period of IOP elevation, the optic nerve progressively
degenerates from 10 months onwards and degeneration is almost complete by
12 months of age (>70% of eyes have severe glaucoma)71. We chose the 9-month
time point for RNA-sequencing analysis, as the majority of D2 eyes at this time
point have intact axons despite experiencing high IOP, thereby providing us an
avenue to capture very early disease relevant molecular changes prior to any
noticeable axonal degeneration. We employed HC of transcriptomic datasets to
generate unbiased unique clusters based on gene expression patterns within
D2 samples. We identified four distinct groups; D2 group 1 being tran-
scriptomically identical to the control strain (D2-Gpnmb+); and D2 groups 2–4
exhibiting increasing levels of dissimilarity compared to the control group at a
transcriptomic level29. We compared gene expression profiles of each of the D2
groups with the control group. Out of the 28 genes that were implicated in the 95%
credible set of variants, some did not have mouse homologs or available data (e.g.,
LOC105378189, LOC145783, LMX1B, and ZNF280D). We also examined the
expression of TMTC2 as our lead SNP that reached genome-wide level of sig-
nificance in the GERA discovery cohort was near this gene. However, the true
causal variant at this locus has <5% chance of being within TMTC2. We conducted
adjustment for multiple testing using FDR (q), and genes were considered to be
significantly differentially expressed at an FDR < 0.05.
We used the DATGAN software30 to assess the expression of the genes that
contained associated 95% credible set variants, in optic nerve head punches of D2
mouse model of glaucoma (http://glaucomadb.jax.org/glaucoma (doi:10.1186/
1471-2164-12-429)). Briefly, the optic nerve head was dissected and profiled using
Mouse 430 v2 arrays (Affymetrix) for 50 DBA/2J eyes and 10 DBA/2J-Gpnmb+
controls. HC was performed to identify groups of eyes undergoing molecular
changes prior to morphological changes in glaucoma. Eyes were clustered into
different stages using the expression profiles from the optic nerve head (Accession
number: GSE26299)30. Data represent the log2 fold change and q-value between D2
and D2.Gpnmb+ (control) samples. q-Values < 0.05 were considered significant.
HTM cell culture and transfection. Experiments were performed utilizing pre-
viously characterized HTM cell line NTM-573 (gift from Gulab Zode, University of
North Texas Health Science, Fort Worth, Texas). HTM cells were cultured in
Dulbecco’s modified Eagle’s medium and F12 containing 10% fetal bovine serum
(FBS). For gene silencing, we used two separate siRNAs targeting different regions
of FMNL2. siRNA1: SMARTpool ON-TARGETplus FMNL2 siRNA (Dharmacon,
#Cat L-031993-01). siRNA2: SMARTpool siGENOME FMNL2 siRNA (Dharma-
con #Cat M-031993-01). Non-targeting siRNA (Dharmacon #Cat D-001810-01)
was used as a control siRNA. HTM cells were transfected either with FMNL2
siRNA1, FMNL2 siRNA2, or control siRNA. Briefly, 2 × 105 cells were added to
wells containing siRNAs to achieve a final siRNA concentration of 100 nM. Reverse
transfection was performed using Lipofectamine RNAiMAX (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions and the cells were cultured for
about 48 h to suppress expression of FMNL2 before utilizing them for phenotypic
characterization.
Quantitative real-time polymerase chain reaction. Total RNA was isolated from
siRNA-transfected HTM cells using the Qiagen RNeasy with on-column DNase I
treatment (Qiagen, Valencia, CA, USA) and reverse transcribed using the iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Quantitative real-time poly-
merase chain reaction was performed on a Bio-Rad C1000 Thermal Cycler/CF96
Real-Time System using SsoAdvancedTM SYBR Green® Supermix (Bio-Rad). The
primer sets used in our experiments are listed in Supplementary Table 12. Each
reaction was run in technical duplicates and a minimum of four biological repli-
cates used per group. The relative expression level of each gene was normalized to
housekeeping genes (ACTB and MAPK1) and analyzed using the CFX manager
software (Bio-Rad).
Phalloidin staining and cell morphology and counting. Following FMNL2 gene
silencing using siRNAs for 24 h, the HTM cells were serum-starved for another 24
h (no FBS). For the FBS-treated groups (+FBS), cell were exposed to media con-
taining 10% FBS for 10 min or 1 h. HTM cells were then fixed with 3.7% paraf-
ormaldehyde and permeabilized using phosphate-buffered saline (PBS) containing
0.1% Triton X-100. To assess assembly of filamentous actin (F-actin), the HTM
cells were then incubated with PBS containing 2 μM fluorescein isothiocyanate-
labeled phalloidin for 30 min at 37 °C and finally mounted on a slide using
VECTASHIELD mounting medium containing DAPI (Vector Laboratories Bur-
lingame, CA, USA). Cells were visualized under fluorescence microscope (Zeiss
LSM 700 laser scanning confocal microscope) to assess assembly of actin filament/
stress fibers. To quantify changes in cellular morphology, the cells were categorized
into three groups based on their shape, (1) rounded/deformed: cells that adhere
poorly and appear as deformed or round; (2) intermediate: cells showing modest
spreading; and (3) spread: cells that are well spread. Proportion of cells in each
group was calculated and expressed as percentage. Three independent experiments
were performed for each condition. At least 400 cells were counted for each
experiment. The Pearson’ chi-squared test was performed to evaluate the statistical
significance among the groups. We used 2 × 2 and 2 × 3 contingency tables for
−FBS and +FBS conditions, respectively.
Mice and husbandry. The Lmx1bV265D allele was backcrossed to the C57BL/6J
(B6) and 129SvEvTac strain backgrounds for six or more generations. This allele is
also known as the Lmx1bIcst39. Strains for backcrossing were obtained from The
Jackson Laboratory (Bar Harbor, ME, USA). The Lmx1bQ82X allele is an inde-
pendent and previously uncharacterized ENU-induced allele that was generated on
a DBA/2J (D2) strain background that has a genetic sensitizer and is WT for the
Gpnmb+ gene but by itself does not develop high IOP or glaucoma (D2.Cg-Gpnmb
+Cyp1b1tm1Gonz strain background). Whole-genome sequencing (WGS) of the G1
with the Lmx1bQ82X allele allowed genetic mapping on this same strain background
using custom markers developed from the pool of incidental mutations identified
via WGS. The phenotype was mapped using over 500 meioses to a 6.7-Mb region
where the Lmx1bQ82Xallele is the only mutation predicted to affect gene function.
The Animal Care and Use Committee of The Jackson Laboratory approved all
experimental protocols. Mutant and control littermates were housed together in
cages with Alpha-Dri bedding covered with polyester filters. Cages were main-
tained in an environment kept at 21 °C with a 14-h light:10-h dark cycle.
Genotyping of the Lmx1b allele. Genotype of the Lmx1bV265D and Lmx1b+ alleles
was determined using an allele-specific PCR protocol. Genomic DNA was PCR
amplified with forward primer for the V265D allele 5′-TCAGCGTGCGTGTGG
TCCTGGA-3′, the forward primer for the WT allele 5′-GACATTGGCAGCAG
AGACAGGCCGAGGCGTGCGTGTGGTCCATGT-3′, and the reverse primer
5′-ACACAAGCCTCTGCCTCCTT-3′. This same allele was previously named
lcst39. Genomic DNA was PCR amplified using the following program: (1) 95 °C
for 2 min; (2) 95 °C for 15 s; (3) 57 °C for 20 s; (4) 72 °C for 30 s; (5) repeat steps
2–4 35 times; and (6) 72 °C for 7 min. A volume of 5 μl of sample was run on a 3%
agarose gel. The WT allele amplifies a 175-base pair fragment and the V265D allele
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amplifies a 152-base pair fragment. Genotyping of the Lmx1bQ82X and Lmx1b+
alleles was determined by direct Sanger sequencing of a specific PCR product.
Genomic DNA was PCR amplified with forward primer 5′-CTTTGAGCC
ATCGGAGCTG-3′ and reverse primer 5′-ATCTCCGACCGCTTCCTGAT-3′
using the following program: (1) 94 °C for 3 min; (2) 94 °C for 30 s; (3) 57 °C for 30
s; (4) 72 °C for 1 min; (5) repeat steps 2–4 35 times; and (6) 72 °C for 5 min. PCR
products were purified and sequenced by the Genome Technologies service at The
Jackson Laboratory.
Clinical examination. Detailed clinical evaluations were performed at 9 months of
age using a slit lamp biomicroscope and photographed with a ×40 objective lens.
Phenotypic evaluation included iris structure, pupillary abnormalities, generalized
corneal haze, anterior and posterior synechia, corneal opacity, hyphaema, hypop-
yon, corneal pyogenic granuloma, vascularized scarred cornea, buphthalmos, cat-
aracts, and deepening of the anterior chamber. Detailed examination of at least 30
eyes from each strain and genotype was performed. All cohorts included male and
female mice.
IOP measurement. IOP was measured using the microneedle method as pre-
viously described in detail74. Briefly, mice were acclimatized to the procedure room
and anesthetized via an intraperitoneal injection of a mixture of ketamine (99 mg/
kg; Ketlar, Parke-Davis, Paramus, NJ) and xylazine (9 mg/kg; Rompun, Phoenix
Pharmaceutical, St. Joseph, MO) prior to IOP assessment—a procedure that does
not alter IOP in the experimental window74. All cohorts included male and female
mice. The IOPs of B6 mice were assessed in parallel with experimental mice as a
methodological control to ensure proper calibration and equipment function. The
IOP values are highly variable in B6.Lmx1bV265D/+ eyes. Lmx1b mutants have
abnormal corneas that are often stretched and sometimes perforate, and this
perforation results in lower IOP values, which may explain the greater spread of
IOP values in B6 Lmx1b mutants. To evaluate the change in the range of IOP
values in Lmx1b mutant eyes across strains relative to controls, we used k-means
clustering. We set k= 3 for each individual group. The cluster with the highest IOP
values was taken from each group and a one-way analysis of variance was per-
formed. Tukey’s honest significance difference was used to compare the means
between Lmx1b mutant and WT mice within each strain.
Ocular and optic nerve histological analysis. Enucleated eyes were fixed for
plastic sectioning as described in detail75. Serial sagittal sections were collected,
stained with hematoxylin and eosin, and analyzed for pathologic alterations.
Intracranial portions of optic nerves were dissected, processed, and analyzed as
previously described and validated71. Briefly, we stained optic nerve cross sections
with para-phenylenediamine (PPD) and then weinvestigated for glaucomatous
damage. Because PPD stain differently stains the myelin sheaths and the axoplasm
of healthy axons compared to those from sick or dying axons, we were able to
detect axon damage and loss in a very sensitive way. The degree of nerve damage
was assigned using a well-established protocol that has been extensively validated
against axon counting71,76. Nerves with severe degeneration have >50% axon loss
compared to controls, nerves with moderate moderate degeneration has on 30%
average axon loss while nerves with no glaucoma are indistinguishable from
controls. To determine whether optic nerve damage levels were dependent on
Lmx1b genotype, we compared mutant and control mice using Fisher’s exact test,
with P < 0.01 considered significant.
MicronIV and image-guided optical coherence tomography. Optical coherence
tomography (OCT) paired with the MicronIV: Retinal Imaging Microscope
(Phoenix Research Labs) was used to assess the retina and optic nerve head in vivo.
Mice were subject to pupillary dilation with a drop of 1% solution of cyclopentolate
hydrochloride ophthalmic solution (Akorn, Inc.) that was topically applied to the
cornea. Mice were anesthetized as previously described (see methods, IOP mea-
surement). Mice were secured on a rotating stage and imaged using OCT per the
manufacturer’s directions.
Data availability. Genotype data of GERA participants are available from the
database of Genotypes and Phenotypes (dbGaP) under accession phs000674.v2.p2.
This includes individuals who consented to having their data shared with dbGaP.
The complete GERA data are available upon application to the KP Research Bank
(https://researchbank.kaiserpermanente.org/). The meta-analysis GWAS summary
statistics are available from the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.
uk/gwas/downloads/summary-statistics). The genotype data and the glaucoma
phenotype of UKB participants are available upon request from (www.ukbiobank.
ac.uk). The RNA-seq and microarray datasets utilized in the study were
deposited previously on NCBI, accession number GSE90654 and GSE26299
respectively.
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